Previous 10 |
ContraFect (CFRX) trades 8.4% down after hours on commencing an underwritten public offering of shares; underwriters granted 30-day option to purchase up to an additional 15% of the shares.Offer actual size, terms have not yet been disclosed.Net proceeds to be used for funding the c...
BARDA awarded ContraFect (CFRX) cost-share contract wherein the company will receive $9.8M in initial funding and up to an additional $77M; shares rallied 20.9% higher after hoursInitial funding will be used to support ContraFect’s ongoing pivotal Phase 3 DISRUPT (Direct Lysis of&...
BARDA to provide funding for the ongoing Phase 3 DISRUPT study of exebacase for the treatment of patients with Staph aureus bloodstream infections Results from the Phase 3 DISRUPT study interim futility analysis anticipated in H2 2021 Phase 3 DISRUPT study has ...
ContraFect failed to show superiority in its Phase 2 trial. The company hopes Exebacase can show significant improvements for patients diagnosed with MRSA. Many risks lay ahead and ContraFect is still no more than a speculative investment. For further details see: Contra...
News, Short Squeeze, Breakout and More Instantly...
ContraFect Corporation Company Name:
CFRX Stock Symbol:
NASDAQ Market:
ContraFect Corporation Website:
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
ContraFect Corporation (CFRX) is expected to report $-0.66 for Q3 2023